LETTERS

Rejoinder to Eigenmann PA, Haenggeli CA, Food colourings and preservatives—allergy and hyperactivity (Lancet 2004;364:823–4) and an erratum

Eigenmann and Haenggeli have commented on a paper we recently published on food additives and hyperactivity in children.1 This commentary gives a seriously misleading account of the findings of the study. Eigenmann and Haenggeli claim that “the term ‘developmentally delayed’ seems to be used synonymous to ADHD”. We deliberately did not use the term ADHD as a criterion for recruitment into the study. This is a diagnostic term requiring a set of explicit criteria to be met and is of doubtful value when applied to 3 year olds. The definition of hyperactivity we used for this study was one based on the risk of subsequent behavioural difficulties in middle childhood which we had established previously in a longitudinal study of an epidemiologically ascertained sample of 3 years olds.2

The study used screens for atopy (AT) and for hyperactivity (HA) applied to a total population sample to identify cases for the following design: “Children were entered into the four group randomised, placebo controlled, double blind, crossover challenge study. The four groups were in a 2 x 2 between group design with the following groups: HA/AT, non-HA/AT, HA/non-AT, and non-HA/non-AT.”3 Eigenmann and Haenggeli observe that “families interested in hyperactivity seem to be over-represented” and on this basis conclude that “results from this study should not lead to recommendations for the general population”. The presence of hyperactivity was one of the inclusion criteria of the food challenge phase of the study and consequently occurs in about half of the cases. A substantial proportion of children were included in the food challenge phase by design. Full details of participant flow were given in a diagram (fig 1 in our paper) as recommended in the CONSORT statement for reporting randomised trials.4

The separate issue of sample attrition through each of the stages of the study was considered carefully and we concluded that the findings from the group completing the food challenge phase would indeed hold for the general population.

The study found significantly greater increases in hyperactive behaviour reported by parents when the children were given the active compared to the placebo challenge. The statement by Eigenmann and Haenggeli that “parents’ observations can be easily explained by their expectations” is puzzling. The parents, children, and the person collecting the behaviour ratings were blind as to the food challenge being taken by the child over these periods. Consequently, “expectations” cannot account for the effects we identified based on changes during the active and placebo periods. This does not hold for the reduction in hyperactivity we observed during the withdrawal phase which, as we discussed in the paper, was not blinded and was greater than that for the placebo versus active periods. This would be expected if the withdrawal effect alone was influenced by parental expectations.

The final part of the Eigenmann and Haenggeli commentary is concerned with the use of diet changes as treatments for hyperactivity. Our study showed that the effects of food colourings and the benzoate preservative were not restricted to or more strongly present for children with atopy or hyperactivity. Consequently our conclusions did not relate to the treatment of children with hyperactivity but rather to the preventive public health issue of whether food additives are having a general detrimental effect on children’s behaviour. The final conclusion from the paper was “…if additives have an effect at all, it is via a pharmacological effect which is best exemplified by the non-IgE dependent histamine release. We believe that this suggests that benefit would accrue for all children if artificial food colours and benzoate preservatives were removed from their diet. These findings are sufficiently strong to warrant attempts at replication in other general population samples and to examine whether similar benefits of the removal of artificial colourings and sodium benzoate from the diet could be identified in community samples at older ages.” We are now conducting just such a replication.

Erratum

While preparing this rejoinder, we have discovered an error in the reporting of the composition of the above mix in the paper. The sentence that reads:

“The active drink included 20 mg in total of artificial food colourings (sunset yellow, tartrazine, carmoisin, and ponceau 4R; 5 mg of each) (Forrester Wood, Oldham, UK) and 45 mg of sodium benzoate (J Loveridge, Southampton, UK).”1

should have read:

“The active drink included 20 mg in total of artificial food colourings (sunset yellow 5 mg, tartrazine 7.5 mg, carmoisin 2.5 mg, and ponceau 4R 5 mg) (Forrester Wood, Oldham, UK) and 45 mg of sodium benzoate (J Loveridge, Southampton, UK).”

References


Developmental delay versus developmental impairment

The use of the term delay should be replaced by impairment because of parental perception of the meaning of delay as applied to development.

I would like to draw attention to my experience of parents’ perception of the language we use in describing children and their ability.

It is common practice to refer to children who are detected to be significantly behind in achieving developmental milestones to be developmentally delayed. In talking to prospective adoptive parents I have become aware of how misleading this phrase is in describing to prospective adopters what we mean.

The general population has a perception of delay to mean something that will get there in the end, rather like a train being delayed, but reaching its destination eventually. It has taught me to use the term impairment rather than delay so that I do transmit to prospective adopters the true meaning of what I am trying to describe.

I wonder if as a profession we would consider examining our use of this term delay and possibly re-educating our profession to use the term impairment because it does not suggest that the child will be normal eventually.

A Bosley
North Devon Healthcare Trust, North Devon District Hospital, Raleigh Park, Barnstaple EX31 4BJ, UK;
alan.bosley@ndevon.swest.nhs.uk

Palivizumab prophylaxis in haemodynamically significant congenital heart disease

Patients with congenital heart disease (CHD) have been reported by many authors to have high rates of hospitalisation, morbidity, and mortality associated with respiratory syncytial virus (RSV) lower respiratory tract illness.1 However, in a recent paper in Archives of Disease in Childhood, Duppenthaler et al reported a substantially lower incidence of...
RSV hospitalisation in patients with “haemodynamically significant” CHD. They suggest that the rate of hospitalisation in their population of patients from the Canton of Bern, Switzerland was as much as four times lower than rates previously reported in the United States. Based on these results they concluded that the unrestricted use of palivizumab to prevent RSV hospitalisation is not justified.

There are several possible methodological reasons for the disparity in RSV hospitalisation rates in the calculations of both the numerator and denominator. With respect to the numerator, Dr Duppenthaler’s methods would miss all of the nosocomial RSV disease. Furthermore, ascertaining the true incidence of RSV hospitalisation would require that all CHD patients admitted to the hospital undergo RSV screening, as was done in the international multicentre trial, not just those with symptoms judged typical of RSV.

Finally, in a previous paper by the same authors in the first four years of the study (1997/98–2000/01), 12 of 497 patients studied aged <5 years were identified with CHD compared to 6 of 449 aged <2 years in this study. In a previous study encompassed children under the age of 5, the difference of six patients between the first study and this one would imply that children who were hospitalised were between the ages of 2 and 5 (making a strong case for palivizumab prophylaxis in that age group), or they were deemed to have haemodynamically insignificant heart disease (making a case for prophylaxis in this group or questioning the definition of haemodynamically significant heart disease).

With respect to the denominator, the authors used the International Classification of Diseases (ICD) coding as a screen for patients who undergo RSV screening, as was done in the international multicentre trial, not just those with symptoms judged typical of RSV.

For instance, in a previous paper by the same authors in the first four years of the study (1997/98–2000/01), 12 of 497 patients studied aged <5 years were identified with CHD compared to 6 of 449 aged <2 years in this study. In a previous study encompassed children under the age of 5, the difference of six patients between the first study and this one would imply that children who were hospitalised were between the ages of 2 and 5 (making a strong case for palivizumab prophylaxis in that age group), or they were deemed to have haemodynamically insignificant heart disease (making a case for prophylaxis in this group or questioning the definition of haemodynamically significant heart disease).

Finally, in a previous paper by the same authors in the first four years of the study (1997/98–2000/01), 12 of 497 patients studied aged <5 years were identified with CHD compared to 6 of 449 aged <2 years in this study. In a previous study encompassed children under the age of 5, the difference of six patients between the first study and this one would imply that children who were hospitalised were between the ages of 2 and 5 (making a strong case for palivizumab prophylaxis in that age group), or they were deemed to have haemodynamically insignificant heart disease (making a case for prophylaxis in this group or questioning the definition of haemodynamically significant heart disease).

With respect to the denominator, the authors used the International Classification of Diseases (ICD) coding as a screen for patients who undergo RSV screening, as was done in the international multicentre trial, not just those with symptoms judged typical of RSV.

For instance, in a previous paper by the same authors in the first four years of the study (1997/98–2000/01), 12 of 497 patients studied aged <5 years were identified with CHD compared to 6 of 449 aged <2 years in this study. In a previous study encompassed children under the age of 5, the difference of six patients between the first study and this one would imply that children who were hospitalised were between the ages of 2 and 5 (making a strong case for palivizumab prophylaxis in that age group), or they were deemed to have haemodynamically insignificant heart disease (making a case for prophylaxis in this group or questioning the definition of haemodynamically significant heart disease).

With respect to the denominator, the authors used the International Classification of Diseases (ICD) coding as a screen for patients who undergo RSV screening, as was done in the international multicentre trial, not just those with symptoms judged typical of RSV.

For instance, in a previous paper by the same authors in the first four years of the study (1997/98–2000/01), 12 of 497 patients studied aged <5 years were identified with CHD compared to 6 of 449 aged <2 years in this study. In a previous study encompassed children under the age of 5, the difference of six patients between the first study and this one would imply that children who were hospitalised were between the ages of 2 and 5 (making a strong case for palivizumab prophylaxis in that age group), or they were deemed to have haemodynamically insignificant heart disease (making a case for prophylaxis in this group or questioning the definition of haemodynamically significant heart disease).

With respect to the denominator, the authors used the International Classification of Diseases (ICD) coding as a screen for patients who undergo RSV screening, as was done in the international multicentre trial, not just those with symptoms judged typical of RSV.

For instance, in a previous paper by the same authors in the first four years of the study (1997/98–2000/01), 12 of 497 patients studied aged <5 years were identified with CHD compared to 6 of 449 aged <2 years in this study. In a previous study encompassed children under the age of 5, the difference of six patients between the first study and this one would imply that children who were hospitalised were between the ages of 2 and 5 (making a strong case for palivizumab prophylaxis in that age group), or they were deemed to have haemodynamically insignificant heart disease (making a case for prophylaxis in this group or questioning the definition of haemodynamically significant heart disease).

With respect to the denominator, the authors used the International Classification of Diseases (ICD) coding as a screen for patients who undergo RSV screening, as was done in the international multicentre trial, not just those with symptoms judged typical of RSV.

For instance, in a previous paper by the same authors in the first four years of the study (1997/98–2000/01), 12 of 497 patients studied aged <5 years were identified with CHD compared to 6 of 449 aged <2 years in this study. In a previous study encompassed children under the age of 5, the difference of six patients between the first study and this one would imply that children who were hospitalised were between the ages of 2 and 5 (making a strong case for palivizumab prophylaxis in that age group), or they were deemed to have haemodynamically insignificant heart disease (making a case for prophylaxis in this group or questioning the definition of haemodynamically significant heart disease).

With respect to the denominator, the authors used the International Classification of Diseases (ICD) coding as a screen for patients who undergo RSV screening, as was done in the international multicentre trial, not just those with symptoms judged typical of RSV.

For instance, in a previous paper by the same authors in the first four years of the study (1997/98–2000/01), 12 of 497 patients studied aged <5 years were identified with CHD compared to 6 of 449 aged <2 years in this study. In a previous study encompassed children under the age of 5, the difference of six patients between the first study and this one would imply that children who were hospitalised were between the ages of 2 and 5 (making a strong case for palivizumab prophylaxis in that age group), or they were deemed to have haemodynamically insignificant heart disease (making a case for prophylaxis in this group or questioning the definition of haemodynamically significant heart disease).

With respect to the denominator, the authors used the International Classification of Diseases (ICD) coding as a screen for patients who undergo RSV screening, as was done in the international multicentre trial, not just those with symptoms judged typical of RSV.
Feltes and Simoes also claim that we got it wrong with the “child-years” and thus over-estimated that denominator by a factor 2. Objection! We agree that RSV exposure only occurs approximately half of the child-years, and that total child-years should be divided by factor 2 for calculation of incidence per child-year of RSV season. However, we compared our incidence rates with those of Boyce and colleagues, which were already corrected for this discrepancy (that is, our data in table 3 were compared to the column entitled “Hospitalisations per 1000 child-years” in table 1 of Boyce’s paper, p. 867, which were multiplied by factor 2). Had we truly committed the mistake claimed by Feltes and Simoes, we would have compared our data with the preceding column in the said table, which is entitled “Incidence” (meaning: hospitalisations per 1000 child-years of RSV season).

Reduction of our denominator by factor 2 was indeed necessary, when children <6 months of age only were investigated. This, however, we did for calculation of the figures in table 3 and we explicitly stated that we did so in the text on page 963. Thus, this allegation again is incorrect in our opinion.

It is true that we used the entire population of non-CHD patients as referent, because we did not have data of sufficient quality for analysis of other individual risk factors. This was clearly stated in the manuscript. However, to claim that such a comparison is “unfair” is difficult to understand, because (1) for comparison we used Boyce’s raw data to calculate non-CHD rates in their population, and (2) in Switzerland, palivizumab has been recommended for children with severe BPD only. Thus, we believe that it does make sense to compare CHD patients to all others who do not receive palivizumab. The very small group of children with severe BPD makes no substantial difference here.

We agree with Feltes and Simoes that NNT should not play a major role when it comes to providing optimal care for children with CHD. However, to the best of our knowledge, the new 2004 Swiss recommendations for the administration of palivizumab include children <1 year of age with surgically corrected, haemodynamically significant CHD and cyanotic CHD or severe hypertension or diastolic failure, as soon as the distributor of palivizumab successfully applies for mandatory coverage by the health insurance companies. If, however, resources are limited, and they increasingly are in many European countries, cost-effectiveness analyses including NNT do play a role when authorities have to weigh different new interventions against each other.

In summary, we believe that Feltes and Simoes create a largely incorrect worst case scenario of what could have gone wrong with our study. As elaborated above, we believe that our data are correct and—with the limitations described in the paper—reflect the current epidemiology in the study area.

C Aebi
Department of Pediatrics, University of Bern, CH-3010
Bern, Switzerland; christoph.aebi@insel.ch

References
1 Duppenthaler A, Ammann RA, Gorgievski-Hrisoho M, et al. Low incidence of respiratory syncytial virus hospitalizations in


The Royal College of Paediatrics and Child Health flagship meeting: is it value for money?
The most recent Newsletter from the Royal College of Paediatrics and Child Health (RCPCH) was accompanied by a call for abstracts for the 9th Spring Meeting. An article in a recent RCPCH trainee’s newsletter from the chairman of the trainees’ committee expressed disappointment at the level of attendance by trainees, and that those who did attend left almost immediately after giving their presentation. This is supported by official figures from the RCPCH which show the lowest number of SHO and SpR attendees at the 2004 meeting over the past six years (table 1). SpR attendances at the 2004 meeting accounted for less than one quarter of total attendees and SHO attendances for only 2%. Why is this happening?

I postulate that it is simply too expensive. To attend for the three full day sessions at the RCPCH meeting will cost in excess of £500. The total sum involved is in excess of most trainees’ annual study leave budget. Indeed with the financial constraints existing in most NHS trusts, study leave budgets are often not sufficiently reimbursed, leaving trainees to supplement fees from their own pocket.

In contrast to most other countries, no concessions are driven for trainees. The Society for Paediatric Research in the United States offers significant reductions in subscription fees for their annual meeting. This concession for trainees is mirrored by flagship paediatric meetings in most European countries, including the Congres de la Societe´ Fran ¸aise de Pe ´diatrie, which are attended by a far greater percentage of trainees than the RCPCH meeting.

If the RCPCH is serious about campaigning for a greater number of junior attendees at the Spring Meeting then it must follow the example of most other major paediatric haltings worldwide and offer financial concessions to the future paediatricians they hope to train.

D P Kenny
Department of Paediatric Cardiology, Bristol Childrens Hospital, UK; damienkenny@doctors.org.uk

Competing interests: none declared

Reference

Reply by the RCPCH
I am pleased to have the opportunity to respond on behalf of the Academic Board.

The trainee representatives on the Academic Board have taken soundings from their peers and formal approaches have been made to regional advisers, to inform our extensive discussions of these same data.

The data above show a fall in attendance, but do not provide any evidence that the reducing attendance is because the meeting is too expensive. Indeed, during inquiries many other factors were identified—European Working Time Directive, the introduction of shift systems at middle grade, shorter training attachments at Specialist Registrar level are some—which not only have the effect of reducing and availability for visits to the Spring Meeting, but mitigated against research activities by trainees, so reducing their chance of presenting at the Spring Meeting.

The growth of sub-speciality training may also be attracting trainees to specialty groups in the UK and Europe instead of the RCPCH Spring Meeting.

The Academic Board Executive has written to RCPCH college tutors and the chairman and members of the National Association of Clinical Tutors to ensure that trainees are encouraged to attend and given study leave and funding to do so. They are contrary to popular belief, the Spring Meeting does not make money for the College, even when profits from the trade exhibition are included (these latter are far smaller than abroad, because of rules about sponsorship).

The meetings run within a very narrow margin of making a loss. The figures are published in the annual accounts. Concessions for any group would mean an increase in costs for another.

Finally, the venue of the Spring Meeting is regularly reviewed, but there are few alternative venues, when the requirements for simultaneous sessions, technical support, accommodation, and provender are taken into account. Currently, York University offers good value and a fine setting where paediatricians, senior and junior, from the UK and abroad can meet, make and renew
Meningitis is a common cause of convulsive status epilepticus

With the benefit of hindsight from this study, which refuted the perception that convulsive status epilepticus is atypical of acute bacterial meningitis (ABM), cerebrospinal fluid (CSF) sampling might have been more readily undertaken, and perhaps more blood cultures done, given the fact that the latter modality sometimes tests positive even when the blood is normal.

The crux of the matter is how the index of suspicion for meningitis is “packaged”, and the bottom line is that, given the fact that both ABM and tuberculous meningitis (TBM) are eminently amenable to treatment, and without treatment death is an almost invariable outcome for both, common ground must be found in the “packaging” in order to optimise diagnostic potential. A package which does not acknowledge the true prevalence of disease manifestations risks relegating those stigmata to oblivion, the latter being the fate of the blanching maculopapular rash which, most prominently, its prevalence of 13% in meningococcaemia, nevertheless totally escaped mention in the section on ABM in a leading textbook. With a prevalence of 6.5–9.7% in ABM, the CSF which is characterised by normal cellularity and biochemistry is another parameter that deserves greater recognition than is usually the case, especially because this is a feature which may characterise TBM as well.

One view is that, in the latter context, convincing HIV/AIDS is the operative factor for this manifestation of TBM.

What is also evident from the HIV/AIDS epidemic, is that tuberculous patients who harbour HIV virus are more likely to have extrapulmonary tuberculosis than their counterparts who do not have HIV/AIDS. The paradigm shift dictated by the HIV/AIDS era is that the index of suspicion for miliary tuberculosis and, hence, TBM, should be correspondingly higher, and that parallels between ABM and TBM should be more readily recognised. For example, like the four patients reported with ABM in the absence of meningococcal signs, the 8 month old HIV/AIDS patient with TBM reported by Janner et al. also presented without any clinical signs of meningitis.

Fundoscopy is crucial to the index of suspicion of tuberculosis and, hence, TBM, given the fact that the presence of choroidal tubercles will reveal the mycobacterial component even when routine chest radiography has failed to do so. Among 113 confirmed cases of miliary tuberculosis, 12.4% were undetected by chest x-ray. Choroidal tubercles were detected by fundoscopy in five of the 14 x ray negative cases.

The armamentaria for the heightened index of suspicion for TBM as well as for ABM include a more overt acknowledgment of the significance of the blanching maculopapular rash in ABM, routine fundoscopy to detect choroidal tubercles, a greater willingness to take CSF samples and blood cultures in convulsive status epilepticus, and a recognition that a CSF which is normal for cell count and for biochemistry may be a feature of either ABM or TBM, and so may be the total absence of signs of meningeal irritation.

References


BOOK REVIEWS


And it’s only £18, including postage! But how does one review a book like this, a collection of twelve dozen editorials spanning four decades? I thought of the late Ronnie Mac Keith ("I am not your boss, I am your colleague") whose evocative personal memory by Martin rounds off this book, and looked for a bottle of Madeira to accompany my morning coffee and sweet biscuit. All I could find was port, and at once I was there again. Whereas "The glory of language is its flexibility and its failure to obey the rules." Regarding meetings and conferences, he favours the view of Mac Keith that the "greatest benefit results when small groups of 10 to 30 are together for three or four days" with "the intelligent use of guests from the clay tablets of ancient Mesopotamia (p. 205) to Hippocrates to Chaucer, to Little, Osler and Freud, and via the USA to more recent sages. By 1986 (p. 106) "I feel that the dead hand of peer reviewing and conformity hangs heavily over medical journals, whereas "The glory of language is its flexibility and its failure to obey the rules." Regarding meetings and conferences, he favours the view of Mac Keith that the "greatest benefit results when small groups of 10 to 30 are together for three or four days" with "the intelligent use of guests from far-away parts of the world." (p. 61). The Final Editorial of Mac Keith in 2003 (p. 252) includes the immortal lines "Indeed it was Hippocrates who denied that epilepsy was due to the erotic behaviour of the gods, but to some disorder which could be rationally investigated." Much better than erractic.

J B P Stephenson
A PAR is a different trajectory of development that the fetus takes as a result of its intrauterine (or perhaps early postnatal) environment, with the aim of maximising chances of survival to reproductive maturity, in a particular expected postnatal environment. For example, in the pregnant snowshoe hare, stress (due to predation, cold, or starvation, for example) may lead to increased maternal cortisol levels. Cortisol may cross the placenta, and the fetus may detect, via signalling from the mother and placenta, that the external environment is a harsh one. The cortisol levels may enhance maturation of fetal organs, such as the lungs, and prepare the fetus for the rigours of postnatal life. However, it appears that exposure to such high cortisol levels in utero may alter the sensitivity of the hypothalamo-pituitary-adrenal axis, making it hyper-responsive after birth. So the offspring of hares that have been stressed during pregnancy, may be hyper-alert—a predictive adaptive response to the expected postnatal environment. One wonders what the effects of an analogous human PAR might be.

Gluckman and Hanson propose that while we have reached a stage in the 150 000 year history of Homo sapiens where Darwinian evolution is no longer active or has slowed dramatically, the predictive adaptive responses we have evolved now threaten our post-reproductive health, in terms of obesity, type 2 diabetes, atherosclerosis, and hypertension. These responses could be initiated soon after conception, mediated by DNA methylation. What is unclear is the extent to which PARs may play a role in human disease outside the context of birth weight (or rather suboptimal fetal growth) and the metabolic “syndrome X”. Gluckman and Hanson make a case for other diseases such as osteoporosis, cognitive decline, psychosis, and polycystic ovarian syndrome, with varying degrees of persuasiveness.

The message from the book appears to be twofold: that the evidence for PARs playing a role in human disease is a persuasive one, which should not be overlooked in favour of “sexy” genome research; and secondly, that if these hypotheses are correct then this has significant implications for society, and how we try to reduce the burden of disease in later life. Unfortunately, there appear to be few recommendations we can make for optimising the intrauterine, and postnatal, environment to minimise the potentially harmful effects of inappropriate PARs.

The fetal matrix concludes with a call for an increased emphasis on the importance of female health before and during pregnancy, with improved female literacy and education (and therefore, hopefully, avoidance of teenage pregnancy), and nutrition. It therefore sends a message to research funding councils of the potential importance of this area of research, and to politicians about priorities. The book should however be of interest (and thought provoking) to anyone with an interest in perinatal care, human nutrition, and fetal physiology.

A C Breeze
Rejoinder to Eigenmann PA, Haengelli CA, Food colourings and preservatives — allergy and hyperactivity (Lancet 2004; 364:823–4) and an erratum

J Stevenson, B Bateman and J O Warner

Arch Dis Child 2005 90: 875
doi: 10.1136/adc.2005.072157

Updated information and services can be found at:
http://adc.bmj.com/content/90/8/875.1

These include:

References

This article cites 5 articles, 2 of which you can access for free at:
http://adc.bmj.com/content/90/8/875.1#BIBL

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/